A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for atleast 26 weeks prior to the first administration of study intervention

• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) atscreening and baseline

• Total psoriasis area and severity index (PASI) >=12 at screening and baseline

• Total investigator global assessment (IGA) >=3 at screening and baseline

• Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

• Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)

• Current drug-induced psoriasis (for example, a new onset of psoriasis or anexacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)

• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolledrenal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,hematologic, rheumatologic, psychiatric, or metabolic disturbances

• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib,or to any of the excipients or components of the study intervention

• Major surgical procedure, (for example, requiring general anesthesia) within 8 weeksbefore screening, or will not have fully recovered from surgical procedure, or has asurgical procedure planned during the time the participant is expected toparticipate in the study